Nayak S, Singer A, Greenspan SL, et al. - After a new osteoporotic fracture, secondary fracture prevention intervention for Medicare beneficiaries is very likely to both improve health outcomes and reduce healthcare costs compared with usual care.

• In this population, expansion of its use is strongly recommended. For U.S. Medicare patients aged 65 and older who experience a new osteoporotic fracture, an individual-level state-transition microsimulation model was developed to assess the cost-effectiveness of secondary fracture prevention intervention compared with usual care.

• The findings revealed that individuals who initiated pharmacotherapy and remained adherent were assumed to be treated for 5 years.

• Subsequent fractures, average lifetime costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios in 2020 U.S. dollars per QALY gained were included as outcome measures.

• The study demonstrated that the model time horizon was a lifetime, and the analysis perspective was payer.